Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
1 other identifier
observational
500
1 country
1
Brief Summary
The mechanisms of sensitivity and resistance to oncogene-targeted therapy can be determined from tumor tissue or tumor cell lines derived from available archival samples and/or from standard-of-care re-biopsy upon suspected tumor progression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 23, 2012
CompletedFirst Submitted
Initial submission to the registry
April 17, 2012
CompletedFirst Posted
Study publicly available on registry
April 19, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 30, 2029
February 18, 2026
February 1, 2026
16 years
April 17, 2012
February 13, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To identify baseline and treatment-related somatic changes in the tumor tissue from patients with lung and other thoracic cancers.
To be determined upon funding
Secondary Outcomes (1)
To estimate the proportion of patients that subsequent therapy is altered based on the information acquired from such biopsies
To be determined upon funding
Eligibility Criteria
Patients considered for this study would be undergoing a standard care procedure
You may qualify if:
- Patients undergoing investigation or treatment for thoracic cancers with oncogene-targeted therapies
- Aged 18 years or older
- Either a) have suspected tumor progression or other condition that dictates a standard-of-care palliative, therapeutic, or diagnostic intervention including but not limited to procedures such as bronchoscopic biopsy, computed tomography (CT) or ultra-sound (US)-guided biopsy, thoracentesis, video assisted thoracoscopic (VATS) pleurodesis, lobectomy, adrenalectomy or pleural catheter placement, providing tumor specimen appropriate molecular analysis or b) have previously had biopsy/surgical intervention with tumor tissue at University of Colorado or an outside institution available for medullar analysis.
- Patients must have the ability to understand and willingness to sign an informed consent document.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Colorado, Denverlead
- National Cancer Institute (NCI)collaborator
- National Institutes of Health (NIH)collaborator
Study Sites (1)
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
Biospecimen
Tumor tissue will be acquired from either archival or de novo biopsy material
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Erin Schenk, MD, PhD
University of Colorado, Denver
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 17, 2012
First Posted
April 19, 2012
Study Start
January 23, 2012
Primary Completion (Estimated)
January 1, 2028
Study Completion (Estimated)
January 30, 2029
Last Updated
February 18, 2026
Record last verified: 2026-02